- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.06. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.05. | OnKure Therapeutics GAAP EPS of $1.19 | 1 | Seeking Alpha | ||
| 06.05. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 06.05. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 154 | GlobeNewswire (Europe) | -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's... ► Artikel lesen | |
| 06.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | Evercore ISI starts OnKure stock with Outperform rating | 2 | Investing.com | ||
| 18.03. | H.C. Wainwright cuts OnKure Therapeutics price target to $34 | 8 | Investing.com | ||
| 10.03. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 10.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 257 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen | |
| 10.03. | OnKure Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 221 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen | |
| 04.10.24 | OnKure Therapeutics, Inc. Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million | 287 | GlobeNewswire (Europe) | -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Ka), initially in breast cancer -- On track to announce early clinical... ► Artikel lesen | |
| 03.10.24 | Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure | 257 | GlobeNewswire (Europe) | - Combined company to trade on Nasdaq under ticker "OKUR" - Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,110 | -0,45 % | Pfizer - Trotz 250%-Zolldrohung wird das Gewinnziel angehoben | ||
| SANOFI | 82,57 | +0,90 % | Sanofi SA-Aktie heute gut behauptet: Aktienwert steigt (80,41 €) | Die Aktie von Sanofi SA notiert heute fester. Zuletzt zahlten Investoren für die Aktie 80,41 Euro. Für das Wertpapier von Sanofi SA steht gegenwärtig ein Wertanstieg 0,73 Prozent zu Buche. Das Papier... ► Artikel lesen | |
| INNOCAN PHARMA | 0,127 | -8,30 % | Unglaubliche Prognose für Montag setzt Innocan Pharma Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
| ASSEMBLY BIOSCIENCES | 19,900 | -2,45 % | Assembly Biosciences: Mit Ansage auf 3-Jahres-Hoch! | Ich hatte Assembly Biosciences (WKN: A402CB) zum Top-Favoriten 2025 ausgerufen, eine Neubewertung in Aussicht gestellt und zuletzt einen Ausbruch angekündigt. Seit April steht nun ein Kursgewinn von... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 19,600 | +1,03 % | Nektar Therapeutics Reports Second Quarter 2025 Financial Results | SAN FRANCISCO, Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025.
Cash... ► Artikel lesen | |
| JAGUAR HEALTH | 2,415 | 0,00 % | Jaguar Health, Inc.: Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates | Click here to registerCompany plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference... ► Artikel lesen | |
| ROYALTY PHARMA | 30,950 | -0,80 % | Royalty Pharma Plc Q2 Income Retreats | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) released a profit for second quarter that Drops, from the same period last yearThe company's earnings came in at $30.17 million, or $0.07 per... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 40,460 | -2,67 % | BridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales | ||
| CORBUS PHARMACEUTICALS | 7,650 | +2,68 % | Corbus Pharma's Q2 Net Loss Widens | ||
| SOLIGENIX | 2,570 | 0,00 % | SOLIGENIX, INC.: Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease | Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company)... ► Artikel lesen | |
| KALA BIO | 6,325 | +1,61 % | KALA BIO, Inc.: KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update | -- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9... ► Artikel lesen | |
| MEI PHARMA | 4,855 | 0,00 % | MEI Pharma: Litecoin-Kauf über 100 Millionen Dollar - und jetzt? | MEI Pharma initiiert seine Litecoin-Treasury-Strategie mit einer ersten großen Akquisition der zukunftsträchtigen Kryptowährung. Anleger können langfristig profitieren. 110 Millionen US$ in Litecoin... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,420 | +0,78 % | Aclaris Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| NEUROGENE | 16,950 | -1,51 % | Neurogene GAAP EPS of -$1.05 | ||
| LYRA THERAPEUTICS | 6,715 | 0,00 % | Lyra Therapeutics, Inc. - 10-Q, Quarterly Report |
ONKURE THERAPEUTICS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.